NewAmsterdam Pharma Company NV at Goldman Sachs Healthcare Conference Transcript
NewAmsterdam, very pleased to have Michael, welcome. Notes -- can I give you the opportunity to maybe just level set us and make some opening framing remarks on the company?
Sure. Thanks. Thanks, everyone, for being here. We've had a really productive year firing on all cylinders. I mean our -- all our trials are rolling along on schedule or ahead of schedule.
Of course, the most important being PREVAIL, which is our 9,500 patient outcome study and I think we announced just a few months ago that we're going to do an interim analysis based on a number of factors, we can go into more detail, but that inter-analysis we'll start the actual point at the end of this year, the readout will be in the first quarter of next year.
Well, that's, I guess, one of the most -- that's a great segue into what I think is probably
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
